Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 10/20 | 0.46 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 7/20 | 0.38 |
| ▸ | GLA | P06280 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | THPO | P40225 | 3/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134558 | 1.00 | SCNN1A (0.46) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| Trifluoroacetic Acid SCHEMBL1134627 | 0.94 | SCNN1A (0.41) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| Trifluoroacetic Acid SCHEMBL1134547 | 0.94 | SCNN1A (0.41) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| SCHEMBL2076386 | 0.90 | SCNN1A (0.45) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| SCHEMBL27834089 | 0.89 | CTSA (0.46) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| Trifluoroacetic Acid SCHEMBL1134573 | 0.84 | SCNN1A (0.40) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| SCHEMBL1428331 | 0.83 | SCNN1A (0.40) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| SCHEMBL1134532 | 0.83 | SCNN1A (0.40) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| SCHEMBL17809068 | 0.81 | SCNN1A (0.47) | SCNN1ACTSAALDH1A1HSD17B10KDM4E | |
| SCHEMBL1134600 | 0.81 | SCNN1A (0.47) | SCNN1ACTSAALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | claimed |
| US-8664228-B2 | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8664228-B2 | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| EP-2285785-B1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | US | disclosed |
| EP-2285785-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009138378-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059989-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES | CFTR, SCN5A, SCNN1B | SCNN1A 7/4885CTSA 3969/4885ALDH1A1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.